Agenus (FRA:AJ8) Total Liabilities: €328.6 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:AJ8 Agenus Inc FRA:AJ8
48 GF Score
Price €6.10
GF Value €3.22
Valuation Significantly Overvalued
! 12 Warning Signs
View Full Analysis

What is Agenus Total Liabilities?

Agenus FRA:AJ8 -3.94% 48 Total Liabilities is €328.6 Mil as of Jun. 2026. GuruFocus rates FRA:AJ8 with a GF Score™ of 48/100 and a GF Value™ of €3.22 (Significantly Overvalued). The stock has 12 warning signs investors should review.

Agenus's Total Liabilities for the quarter that ended in Jun. 2026 was €328.6 Mil.

Agenus's quarterly Total Liabilities declined from Dec. 2025 (€430.98 Mil) to Mar. 2026 (€358.49 Mil) and declined from Mar. 2026 (€358.49 Mil) to Jun. 2026 (€328.57 Mil).

Agenus's annual Total Liabilities increased from Dec. 2023 (€423.93 Mil) to Dec. 2024 (€508.72 Mil) but then declined from Dec. 2024 (€508.72 Mil) to Dec. 2025 (€430.98 Mil).

Agenus Total Liabilities Historical Data

* Premium members only.

The historical data trend for Agenus's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Agenus Total Liabilities Chart

Agenus Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 369.97 442.22 423.93 508.72 430.98

Agenus Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 452.17 438.58 430.98 358.49 328.57
FRA:AJ8
48GF Score
Agenus Inc FRA:AJ8
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Agenus Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Agenus's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=276.26+(8.632+145.111
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0.976+0+0)
=431.0

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=193.685--237.293
=431.0

Agenus's Total Liabilities for the quarter that ended in Jun. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=201.22+(8.279+118.083
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0.992+0+0)
=328.6

Total Liabilities=Total Assets (Q: Jun. 2026 )-Total Equity (Q: Jun. 2026 )
=149.897--178.678
=328.6

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of €328.6 Mil mean?
Agenus (FRA:AJ8) has a Total Liabilities of €328.6 Mil as of Jun. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Agenus and its competitors.
Is Agenus' Total Liabilities too high?
Agenus' current Total Liabilities is €328.6 Mil. Overall, Agenus has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Agenus' Total Liabilities compare to FULC and IRD?
Agenus' Total Liabilities of €328.6 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Agenus and its competitors. Agenus's current Total Liabilities is €328.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Agenus stock overvalued right now?
Based on GuruFocus' analysis, Agenus (FRA:AJ8) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.22, compared to a current price of €6.10 — trading 89.4% above its estimated fair value. The current Total Liabilities is €328.6 Mil. Agenus' overall GF Score™ is 48/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Agenus (FRA:AJ8), the current Total Liabilities is €328.6 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Agenus (FRA:AJ8) Overvalued in 2026?

Based on GuruFocus' analysis, Agenus stock appears to be overvalued. The current stock price of €6.10 is trading 89.4% above its estimated GF Value™ of €3.22. GuruFocus considers Agenus to be Significantly Overvalued.

Key valuation signals for FRA:AJ8:

  • Total Liabilities: €328.6 Mil
  • GF Value™: €3.22 vs. price of €6.10 (89.4% above fair value)
  • GF Score™: 48/100 with 12 warning signs

No single metric tells the full story. See the FRA:AJ8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Agenus Business Description

Other Exchanges AGEN:USA
Address 3 Forbes Road, Lexington, MA, USA, 02421
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.
48GF Score

Get the complete analysis for FRA:AJ8

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.10
Price
€3.22
GF Value